Muestra la distribución de la producción WoS, Scopus y SciELO del autor.
Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.
| Firmas del autor | |
| Nombre | MORA, JUDITH |
| Género | Mujer |
| Área Principal WOS | Biology; Medicine, General & Internal; Medicine, Research & Experimental; |
| Afiliación Principal | Inst Salud Publ Chile |
Publicaciones en Chile
Citas Totales
Afiliaciones Chilenas
| WOS | #Pub |
|---|---|
| Biology | 1 |
| Medicine, General & Internal | 1 |
| Medicine, Research & Experimental | 1 |
| Scopus | #Pub |
|---|---|
| Medicine (All) | 1 |
| SciELO | #Pub |
|---|---|
| Health Sciences | 1 |
| Institución | # Pub |
|---|---|
| Inst Salud Publ Chile | 4 |
| Instituto De Salud Pública De Chile | 4 |
| Instituto De Salud Pública | 1 |
| Instituto De Salud Pública (Isp | 1 |
| Título | Año | Citas | Tipo | Revista | Indexada |
|---|---|---|---|---|---|
| Genetic Characterization Of The Virus Causing H1 N1 Influenza Pandemic In Chile. Analysis Of The First Detected Cases | 2011 | 2 | artículo de investigación | Revista Médica De Chile | WoS SciELO Scopus |
| A Booster Dose Of Corona Vac Increases Neutralizing Antibodies And T Cells That Recognize Delta And Omicron Variants Of Concern | 2022 | 16 | artículo de investigación | M Bio | WoS Scopus |
| Inactivated Vaccine Induced Sars Co V 2 Variant Specific Immunity In Children | 2022 | 3 | artículo de investigación | M Bio | WoS Scopus |
| Differences In The Immune Response Elicited By Two Immunization Schedules With An Inactivated Sars Co V 2 Vaccine In A Randomized Phase 3 Clinical Trial | 2022 | 0 | artículo de investigación | E Life | WoS Scopus |
| Humoral And Cellular Response Induced By A Second Booster Of An Inactivated Sars Co V 2 Vaccine In Adults | 2023 | 0 | artículo de investigación | E Bio Medicine | WoS Scopus |
| Palabra Clave | #Pub |
|---|---|
| sars-cov-2 | 4 |
| coronavac | 3 |
| covid-19 | 3 |
| vaccines | 2 |
| phase 3 clinical trial | 2 |
| keywords coronavac | 1 |
| virus | 1 |
| variants of concern | 1 |
| vaccine | 1 |
| second booster dose | 1 |
| safety | 1 |
| phase iii clinical trial | 1 |
| pediatric | 1 |
| pandemics | 1 |
| omicron variant | 1 |
| non-inferiority | 1 |
| bnt162b2 | 1 |
| influenza a virus | 1 |
| immunogenicity | 1 |
| immunization | 1 |
| humoral immunity | 1 |
| human | 1 |
| h1n1 subtype | 1 |
| coronavac® | 1 |
| coronavac (r) | 1 |
| cellular immunity | 1 |
| brazil | 1 |
| booster dose | 1 |